Evidence map›Paper›PMID 33777184›Full record

SynthesisCardiovascular therapeutics2021

A Critical Overview of Systematic Reviews of Shenfu Injection for Heart Failure.

Jinke Huang, Yanlu Wang, Suihe Huang, Xiaohui Qin, Fang Yan, Min Shen, Yong Huang

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Cardiovascular therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Scientific Evidence of Xuebijing Injection in the Treatment of Sepsis.Evidence-based complementary and alternative medicine : eCAM · 2021
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jinke HuangThe Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province 510120, China.ORCID https://orcid.org/0000-0002-5623-0564
Yanlu WangThe First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province 255014, China.ORCID https://orcid.org/0000-0002-2945-0211
Suihe HuangResearch Base of the Clinical Application of Traditional Chinese Medicine Classics, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong Province 510120, China.ORCID https://orcid.org/0000-0002-1685-1323
Xiaohui QinDepartment of Neurology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong Province 510120, China.ORCID https://orcid.org/0000-0002-2924-9710
Fang YanResearch Base of the Clinical Application of Traditional Chinese Medicine Classics, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong Province 510120, China.ORCID https://orcid.org/0000-0003-3033-1487
Min ShenThe Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province 510120, China.ORCID https://orcid.org/0000-0002-2820-0181
Yong HuangSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong Province 510515, China.ORCID https://orcid.org/0000-0003-2652-8586

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesShenfu Injection (SFI) was widely used in the treatment of heart failure (HF) in China. A plethora of systematic reviews/meta-analyses (SRs/MAs) has been conducted in this research area, although with scattered results. The purpose of this overview was to conduct a comprehensive review to summarize and critically evaluate the existing evidence.

methodsDigital databases were searched for SRs/MAs up to January 28, 2021. Two authors independently screened the reviews and assessed the methodological quality of included SRs/MAs using Assessing the Methodological Quality of Systematic Reviews 2 (AMSTAR-2). Quality of evidence for outcomes evaluated within the reviews was appraised with the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE).

resultsThirteen SRs/MAs met the inclusion criteria. Based on AMSTAR-2, the quality of all SRs/MAs was critically low, because all of them have more than one critical domains that were unmet. Based on GRADE, the evidence quality of 24 outcome measures was low or very low, 27 outcome measures was moderate, and none outcome measure was high. Descriptive analysis showed that SFI was an effective and safe method for HF.

conclusionsThe use of SFI for the treatment of HF may be clinically effective and safe. However, this conclusion must be interpreted cautiously due to the generally low methodological quality and low evidence quality of the included SRs/MAs. More rigorously designed SRs/MAs and RCTs with high methodological quality are necessary for further proof.

Indexed as

Databases, FactualDrugs, Chinese HerbalHeart FailureHumansDrugs, Chinese HerbalShen-Fu

Identifiers

PMID33777184
PMCPMC7960068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.